THE Therapeutic Goods Administration has stressed that the proposed changes to advertising of Schedule 3 medications (PD Fri) are part of a draft new Scheduling Policy Framework which is still subject to public consultation.
In the meantime advertising of S3 products not contained in Appendix H is not permitted, the TGA said.
The above article was sent to subscribers in Pharmacy Daily's issue from 22 Jan 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Jan 18
